Portfolio News

Elizabeth Banks Puts Her Unique Stamp (and Face) on Archer Roose Wine

The deal that Elizabeth Banks has with Archer Roose, a premium canned wine brand, isn’t one of those superficial celebrity endorsements. As co-owner and chief creative officer, the Hollywood multi-hyphenate has embedded herself fully into the brand, both in real life and in a series of wacky ads over the past several years. By extension, and as a running gag, she’s also invaded the professional and personal life of its female founder Marian Leitner. For the latest campaign, Banks has...
Read more...

US winemakers revive sales with SMS marketing, sustainability and innovation

Bring the Wine to the People - As prices of bottles and tasting fees rise across wine country—but especially in premium regions like Napa Valley—winemakers are finding ways to offset declining sales and visits by bringing their wares to their most likely customers. There is nothing better than popping a cork to celebrate a major achievement or momentous occasion. But for younger drinkers who may only want one serving of alcohol, and are looking for something with a lighter carbon...
Read more...

Archer Roose Wines’ Rapid On-Premise Growth Continues, Inking National Distribution at Six New Restaurant and Hospitality Chains

Archer Roose, leading canned wine brand, is stacking up new wins in restaurant and hospitality properties around the country. Beginning now through January 2025, Archer Roose Wines will be placed across Levy Hospitality-served stadiums, arenas and venues, Atrium Hospitality-managed hotels, Vail Resort Group locations, STK Steakhouse and Kona Grill to-go menus, Old Chicago restaurants and Punch Bowl Social entertainment spaces. The new distribution deals come on the heels of recently-forged Archer Roose Wines placements at more than 150 Dave &...
Read more...

RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation

RevBio, Inc., announced that it has received FDA approval to expand its ongoing clinical trial to immediately fixate cranial flaps using TETRANITE®, the company’s bone adhesive biomaterial. The company also received reimbursement coverage from the Centers for Medicare and Medicaid (“CMS”) for the use of TETRANITE to replace metal plates and screws. Previously, RevBio received FDA approval to initiate a first-in-human clinical study for an initial five patients to restore cranial flaps following craniotomy procedures and to repair extradural use...
Read more...

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Corbus Pharmaceuticals Holdings, Inc., an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a monoclonal antibody targeting latent TGFβ activation-by blocking the integrin αVβ8. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo. Read more >>
Read more...

Buffalo Next: CleanFiber secures $20M in federal funds to help expand nationally

With $20 million in grants secured from the U.S. Department of Energy, CleanFiber is opening new plants in Washington and Texas. These grants are part of more than $75 million in financing vehicles, grants, and tax credits the Buffalo-headquartered startup has secured in 2024. The company, which makes building insulation from recycled corrugated cardboard supporting energy efficiency, moved to Buffalo after winning $500,000 in the 43North business competition in 2016. The company was founded in Massachusetts in 2013 and was...
Read more...

Purdue University and Akston Biosciences Bring “First Dose of Hope” in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer

Purdue University and its College of Veterinary Medicine, in partnership with Akston Biosciences Corporation, has initiated the enrollment of dogs with urinary bladder cancer in a clinical trial of a pioneering immunotherapy. The immunotherapy consisting of an anti-cPD-L1 monoclonal antibody (mAb) is designed to target and block the cPD-L1 protein on cancer cells. This, in turn, is expected to enhance the immune system's ability to attack the cancer cells more effectively to improve outcomes and extend life. The strategic partnership...
Read more...

Arcitecta Partners with Wasabi Technologies to Offer Seamless Integration of Wasabi Cloud Storage into Data Workflows via a Single Unified View

Arcitecta, a creative and innovative data management software company, today announced it has partnered with Wasabi Technologies, the hot cloud storage company, enabling organizations to seamlessly and transparently integrate Wasabi’s cloud storage into their workflows. Arcitecta’s flagship product, Mediaflux®, acts as a gateway, allowing users to access Wasabi cloud storage and all their data regardless of where it resides through one unified view to drive informed decision-making, greater insights and business value. While integrating cloud storage into an organization’s workflow...
Read more...

New Vice President of Channel Sales at Aircuity

Jay Kress has been named vice president of channel sales at Aircuity, which provides airflow optimization technology. Kress brings a wealth of experience in sales leadership and strategic partnerships that will help the company’s network of channel partners continue to grow in the market, a press release from Aircuity said. Kress has a proven track record of driving results through collaborative, innovative approaches, and will be instrumental in supporting and expanding relationships, the company said. In his new role, Kress...
Read more...

myBiometry Raises $5 Million in Oversubscribed Seed Round to Advance Next-Generation Asthma and COPD Care

Biometry Inc. (myBiometry), an asthma and COPD diagnostic and remote monitoring company, announced that it has successfully raised $5 million in an oversubscribed Seed funding round. The round was led by Dexcom Ventures, with participation from CareSource Indiana, Elevate Ventures, and other investor groups. This funding will advance the development of the company’s fenoTRACK solution, a breakthrough device designed to empower asthma and COPD patients by providing data to enable early detection of exacerbations. “We’re excited to partner with Dexcom...
Read more...